Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling

Title: Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling
Authors: Brisson, Marc; Laprise, Jean-François; Drolet, Mélanie; Chamberland, Éléonore; Bénard, Élodie; Burger, Emily A; Jit, Mark; Kim, Jane J; Markowitz, Lauri E; Sauvageau, Chantal; Sy, Stephen
Contributors: Canadian Institute of Health Research Foundation; Bill & Melinda Gates Foundation; Single-Dose HPV vaccine consortium - PATH
Source: JNCI Monographs ; volume 2024, issue 67, page 387-399 ; ISSN 1052-6773 1745-6614
Publisher Information: Oxford University Press (OUP)
Publication Year: 2024
Description: Background A concern in high-income countries is that switching to 1-dose human papillomavirus (HPV) vaccination could cause a rebound in HPV infection and cervical cancer if 1-dose efficacy or duration were inferior to 2 doses. Using mathematical modeling and up-to-date trial-based data, we projected the population-level effectiveness of switching from 2-dose to 1-dose vaccination under different vaccine efficacy and duration assumptions in high-income countries. Methods We used HPV-ADVISE (Agent-based Dynamic model for VaccInation and Screening Evaluation), a transmission-dynamic model of HPV infection and cervical cancer, varying key model assumptions to identify those with the greatest impact on projections of HPV-16 and cervical cancer incidence over time: 1) 1-dose vaccine efficacy and vaccine duration, 2) mechanisms of vaccine efficacy and duration over time, 3) midadult (>30 years of age) sexual behavior, 4) progression to cervical cancer among midadults, and 5) vaccination coverage and programs. Results In high-income countries, 1-dose vaccination would cause no appreciable rebound in HPV-16 infection, except for a limited rebound under the most pessimistic assumptions of vaccine duration (average, 25 years), because 1) the switch would occur when HPV prevalence is low because of high 2-dose vaccination coverage and 2) individuals would be protected during their peak ages of sexual activity (
Document Type: article in journal/newspaper
Language: English
DOI: 10.1093/jncimonographs/lgae038
Availability: https://doi.org/10.1093/jncimonographs/lgae038; https://academic.oup.com/jncimono/article-pdf/2024/67/387/60629497/lgae038.pdf
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.98C9390A
Database: BASE